TerminatedPhase 1NCT04245722
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fate Therapeutics
- Principal Investigator
- Fate Trial DisclosureFate Therapeutics
- Intervention
- FT596(drug)
- Enrollment
- 98 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2023
Study locations (9)
- The University of Chicago, Chicago, Illinois, United States
- University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- NYU Langone Health, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Sarah Cannon Research Institute (Tennessee Oncology), Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- SCRI-TTI, San Antonio, Texas, United States
- Swedish Cancer Institute, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04245722 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn